Please use this identifier to cite or link to this item:
ชื่อเรื่อง: Efficacy of intravenous ondansetron to prevent vomiting episodes in acute gastroenteritis: A randomized, double blind, and controlled trial
ผู้แต่ง: Rerksuppaphol S.
Rerksuppaphol L.
Keywords: ondansetron
absence of side effects
acute gastroenteritis
controlled study
double blind procedure
drug cost
drug safety
length of stay
major clinical study
oral rehydration therapy
preschool child
randomized controlled trial
school child
single drug dose
วันที่เผยแพร่: 2010
บทคัดย่อ: Acute gastroenteritis is one of the most common infectious diseases of childhood. Its symptoms are vomiting, diarrhea, and dehydration. In the emergency ward, intravenous rather than oral rehydration is usually preferred because of the high likelihood of emesis. Treatments to reduce emesis are of value in improving the rehydration procedure. Our study is a double-blind randomized trial and proposes the use of ondansetron as an antiemetic drug to treat children with acute gastroenteritis. Seventy-four in-patients, aged 3 months to 15 years, were enrolled and randomly assigned to an ondansetron or placebo group. Inclusion criteria were the diagnosis of acute gastroenteritis and the absence of other diseases or allergies to drugs. A single bolus (0.15 mg/kg) of ondansetron was injected intravenously; normal 0.9% saline solution was used as a placebo. This treatment induced vomiting cessation in the ondansetron group significantly in comparison to the placebo group. The length of the hospital stay and the oral rehydration fluid volume were similar in the two groups and no adverse effects were noticed. Thus, safety, low cost, and overall bene fit of ondansetron treatment suggests that this drug can be administered successfully to children with acute gastroenteritis. © S. Rerksuppaphol and L. Rerksuppaphol 2010.
ISSN: 20367503
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.

Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.